Skip to main content
NASDAQ:LJPC

La Jolla Pharmaceutical Competitors

$3.62
+0.12 (+3.43 %)
(As of 05/14/2021 11:58 AM ET)
Add
Compare
Today's Range
$3.52
$3.65
50-Day Range
$3.46
$4.61
52-Week Range
$3.35
$7.85
Volume3,380 shs
Average Volume744,137 shs
Market Capitalization$99.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.84

Competitors

La Jolla Pharmaceutical (NASDAQ:LJPC) Vs. JNCE, CDAK, AVRO, FUSN, ADVM, and OPT

Should you be buying LJPC stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to La Jolla Pharmaceutical, including Jounce Therapeutics (JNCE), Codiak BioSciences (CDAK), AVROBIO (AVRO), Fusion Pharmaceuticals (FUSN), Adverum Biotechnologies (ADVM), and Opthea (OPT).

Jounce Therapeutics (NASDAQ:JNCE) and La Jolla Pharmaceutical (NASDAQ:LJPC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.

Profitability

This table compares Jounce Therapeutics and La Jolla Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jounce TherapeuticsN/A-72.91%-59.68%
La Jolla Pharmaceutical-205.85%N/A-55.80%

Valuation and Earnings

This table compares Jounce Therapeutics and La Jolla Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jounce Therapeutics$147.87 million2.62$56.82 million$1.664.56
La Jolla Pharmaceutical$23.05 million4.31$-116,510,000.00($4.30)-0.84

Jounce Therapeutics has higher revenue and earnings than La Jolla Pharmaceutical. La Jolla Pharmaceutical is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

60.5% of Jounce Therapeutics shares are held by institutional investors. Comparatively, 74.4% of La Jolla Pharmaceutical shares are held by institutional investors. 44.0% of Jounce Therapeutics shares are held by insiders. Comparatively, 33.4% of La Jolla Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jounce Therapeutics and La Jolla Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jounce Therapeutics11402.50
La Jolla Pharmaceutical00203.00

Jounce Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 104.76%. La Jolla Pharmaceutical has a consensus target price of $11.50, indicating a potential upside of 217.68%. Given La Jolla Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe La Jolla Pharmaceutical is more favorable than Jounce Therapeutics.

Volatility and Risk

Jounce Therapeutics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, La Jolla Pharmaceutical has a beta of 2.84, suggesting that its stock price is 184% more volatile than the S&P 500.

Summary

La Jolla Pharmaceutical beats Jounce Therapeutics on 8 of the 14 factors compared between the two stocks.

Codiak BioSciences (NASDAQ:CDAK) and La Jolla Pharmaceutical (NASDAQ:LJPC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Codiak BioSciences and La Jolla Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Codiak BioSciencesN/AN/AN/A
La Jolla Pharmaceutical-205.85%N/A-55.80%

Valuation & Earnings

This table compares Codiak BioSciences and La Jolla Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codiak BioSciencesN/AN/AN/AN/AN/A
La Jolla Pharmaceutical$23.05 million4.31$-116,510,000.00($4.30)-0.84

Codiak BioSciences has higher earnings, but lower revenue than La Jolla Pharmaceutical.

Institutional and Insider Ownership

74.4% of La Jolla Pharmaceutical shares are held by institutional investors. 33.4% of La Jolla Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Codiak BioSciences and La Jolla Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Codiak BioSciences00303.00
La Jolla Pharmaceutical00203.00

Codiak BioSciences currently has a consensus target price of $30.00, suggesting a potential upside of 67.88%. La Jolla Pharmaceutical has a consensus target price of $11.50, suggesting a potential upside of 217.68%. Given La Jolla Pharmaceutical's higher possible upside, analysts plainly believe La Jolla Pharmaceutical is more favorable than Codiak BioSciences.

Summary

La Jolla Pharmaceutical beats Codiak BioSciences on 4 of the 7 factors compared between the two stocks.

AVROBIO (NASDAQ:AVRO) and La Jolla Pharmaceutical (NASDAQ:LJPC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares AVROBIO and La Jolla Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVROBION/A-51.33%-47.65%
La Jolla Pharmaceutical-205.85%N/A-55.80%

Valuation & Earnings

This table compares AVROBIO and La Jolla Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVROBION/AN/A$-72,960,000.00($2.66)-3.61
La Jolla Pharmaceutical$23.05 million4.31$-116,510,000.00($4.30)-0.84

AVROBIO has higher earnings, but lower revenue than La Jolla Pharmaceutical. AVROBIO is trading at a lower price-to-earnings ratio than La Jolla Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.7% of AVROBIO shares are held by institutional investors. Comparatively, 74.4% of La Jolla Pharmaceutical shares are held by institutional investors. 4.8% of AVROBIO shares are held by insiders. Comparatively, 33.4% of La Jolla Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for AVROBIO and La Jolla Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVROBIO03602.67
La Jolla Pharmaceutical00203.00

AVROBIO currently has a consensus target price of $24.2222, suggesting a potential upside of 151.79%. La Jolla Pharmaceutical has a consensus target price of $11.50, suggesting a potential upside of 217.68%. Given La Jolla Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe La Jolla Pharmaceutical is more favorable than AVROBIO.

Risk & Volatility

AVROBIO has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, La Jolla Pharmaceutical has a beta of 2.84, suggesting that its share price is 184% more volatile than the S&P 500.

Summary

La Jolla Pharmaceutical beats AVROBIO on 7 of the 13 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and La Jolla Pharmaceutical (NASDAQ:LJPC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Fusion Pharmaceuticals and La Jolla Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
La Jolla Pharmaceutical-205.85%N/A-55.80%

Valuation & Earnings

This table compares Fusion Pharmaceuticals and La Jolla Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
La Jolla Pharmaceutical$23.05 million4.31$-116,510,000.00($4.30)-0.84

Fusion Pharmaceuticals has higher earnings, but lower revenue than La Jolla Pharmaceutical.

Institutional and Insider Ownership

61.4% of Fusion Pharmaceuticals shares are held by institutional investors. Comparatively, 74.4% of La Jolla Pharmaceutical shares are held by institutional investors. 33.4% of La Jolla Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Fusion Pharmaceuticals and La Jolla Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
La Jolla Pharmaceutical00203.00

Fusion Pharmaceuticals currently has a consensus target price of $23.6667, suggesting a potential upside of 186.17%. La Jolla Pharmaceutical has a consensus target price of $11.50, suggesting a potential upside of 217.68%. Given La Jolla Pharmaceutical's higher possible upside, analysts plainly believe La Jolla Pharmaceutical is more favorable than Fusion Pharmaceuticals.

Summary

La Jolla Pharmaceutical beats Fusion Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Adverum Biotechnologies (NASDAQ:ADVM) and La Jolla Pharmaceutical (NASDAQ:LJPC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Profitability

This table compares Adverum Biotechnologies and La Jolla Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adverum BiotechnologiesN/A-32.23%-28.02%
La Jolla Pharmaceutical-205.85%N/A-55.80%

Earnings and Valuation

This table compares Adverum Biotechnologies and La Jolla Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$250,000.001,433.77$-64,490,000.00($1.01)-3.62
La Jolla Pharmaceutical$23.05 million4.31$-116,510,000.00($4.30)-0.84

Adverum Biotechnologies has higher earnings, but lower revenue than La Jolla Pharmaceutical. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than La Jolla Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Adverum Biotechnologies has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, La Jolla Pharmaceutical has a beta of 2.84, suggesting that its stock price is 184% more volatile than the S&P 500.

Institutional & Insider Ownership

97.4% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 74.4% of La Jolla Pharmaceutical shares are owned by institutional investors. 12.4% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 33.4% of La Jolla Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Adverum Biotechnologies and La Jolla Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adverum Biotechnologies08202.20
La Jolla Pharmaceutical00203.00

Adverum Biotechnologies currently has a consensus target price of $14.1250, suggesting a potential upside of 285.93%. La Jolla Pharmaceutical has a consensus target price of $11.50, suggesting a potential upside of 217.68%. Given Adverum Biotechnologies' higher possible upside, equities research analysts plainly believe Adverum Biotechnologies is more favorable than La Jolla Pharmaceutical.

Summary

Adverum Biotechnologies beats La Jolla Pharmaceutical on 7 of the 13 factors compared between the two stocks.

Opthea (NASDAQ:OPT) and La Jolla Pharmaceutical (NASDAQ:LJPC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Profitability

This table compares Opthea and La Jolla Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptheaN/AN/AN/A
La Jolla Pharmaceutical-205.85%N/A-55.80%

Earnings and Valuation

This table compares Opthea and La Jolla Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptheaN/AN/AN/AN/AN/A
La Jolla Pharmaceutical$23.05 million4.31$-116,510,000.00($4.30)-0.84

Opthea has higher earnings, but lower revenue than La Jolla Pharmaceutical.

Institutional & Insider Ownership

74.4% of La Jolla Pharmaceutical shares are owned by institutional investors. 33.4% of La Jolla Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Opthea and La Jolla Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Opthea01502.83
La Jolla Pharmaceutical00203.00

Opthea currently has a consensus target price of $36.00, suggesting a potential upside of 348.32%. La Jolla Pharmaceutical has a consensus target price of $11.50, suggesting a potential upside of 217.68%. Given Opthea's higher possible upside, equities research analysts plainly believe Opthea is more favorable than La Jolla Pharmaceutical.


La Jolla Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$7.57+4.5%$370.23 million$147.87 million-2.51
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$17.87+6.8%$367.25 millionN/A0.00Gap Up
AVROBIO logo
AVRO
AVROBIO
1.9$9.60+8.4%$367.12 millionN/A-2.91Earnings Announcement
Analyst Report
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.4$8.27+1.8%$357.39 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.8$3.66+1.1%$354.53 million$250,000.00-2.88Analyst Downgrade
Opthea logo
OPT
Opthea
1.5$8.03+3.5%$348.96 millionN/A0.00Gap Up
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.3$2.05+5.4%$336.80 million$8.15 million-1.64Upcoming Earnings
Gap Up
Surface Oncology logo
SURF
Surface Oncology
1.4$7.72+4.7%$319.64 million$15.36 million-11.70
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.66+2.0%$318.82 million$250,000.00-3.09Earnings Announcement
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.13+1.3%$316.69 million$2.91 million-2.14Analyst Report
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.13+6.7%$315.62 millionN/A0.00Earnings Announcement
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.7$9.44+7.3%$313.73 millionN/A0.00Analyst Report
News Coverage
Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$3.95+3.0%$312.01 million$96.12 million-11.62Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.18+1.8%$272.63 millionN/A-3.37Analyst Report
Analyst Revision
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$9.38+6.4%$218.87 millionN/A-6.85
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.48+4.1%$198.51 million$4.13 million-3.29Earnings Announcement
Analyst Report
News Coverage
Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.73+6.4%$196.47 million$29.35 million-2.01Earnings Announcement
Genfit logo
GNFT
Genfit
1.3$4.11+1.5%$188.14 million$45.88 million-2.09
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$4.50+4.7%$161.85 million$104.39 million-2.74Earnings Announcement
Analyst Report
Analyst Revision
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.43+3.6%$161.22 millionN/A-7.84Earnings Announcement
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.83+4.2%$156.90 million$2.45 million-1.80Upcoming Earnings
News Coverage
Gap Up
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.63+5.0%$152.59 millionN/A-4.64Earnings Announcement
Analyst Revision
News Coverage
PolarityTE logo
PTE
PolarityTE
1.5$1.00+24.3%$150.00 million$5.65 million-0.60Earnings Announcement
Unusual Options Activity
News Coverage
Gap Down
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.79+7.5%$142.47 millionN/A-2.99Earnings Announcement
Analyst Revision
News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.51+7.5%$140.75 millionN/A-1.66
INmune Bio logo
INMB
INmune Bio
1.5$10.32+10.0%$138.73 millionN/A-10.64Analyst Downgrade
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.27+1.6%$133.43 millionN/A0.00Earnings Announcement
Gap Up
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.3$10.00+2.0%$129.76 million$2.33 million0.00News Coverage
Gap Up
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$7.66+2.7%$129.51 millionN/A-2.39Gap Down
Axcella Health logo
AXLA
Axcella Health
1.6$3.43+2.9%$125.61 millionN/A-1.60Analyst Revision
News Coverage
Gap Up
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.34+2.9%$121.45 million$32.12 million-71.85
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.41+5.6%$116.95 millionN/A-3.25
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.81+7.1%$112.36 million$20,000.000.00Upcoming Earnings
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.21+6.8%$112.14 millionN/A-1.52Analyst Revision
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.7$11.00+1.0%$111.36 millionN/A0.00Insider Buying
Dyadic International logo
DYAI
Dyadic International
1.3$3.88+1.0%$105.81 million$1.68 million-11.41Gap Down
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.01+0.5%$97.55 million$20.92 million-1.16Earnings Announcement
News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$9.05+4.1%$97.47 millionN/A0.00Analyst Upgrade
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.00+3.5%$92.30 million$140,000.000.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$6.04+3.8%$90.07 million$3 million-1.94
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$4.60+14.1%$79.56 million$10,000.000.00Upcoming Earnings
Gap Up
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.13+0.9%$65.68 millionN/A-0.90Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.72+2.7%$57.96 million$420,000.00-1.40Earnings Announcement
News Coverage
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.84+1.7%$56.89 million$7.92 million-0.35Earnings Announcement
News Coverage
BioCardia logo
BCDA
BioCardia
1.2$3.50+5.1%$55.75 million$710,000.00-1.80Earnings Announcement
News Coverage
Gap Up
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.68+2.2%$54.10 million$10,000.000.00
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.01+0.0%$50.53 million$1.45 million-0.35
Organovo logo
ONVO
Organovo
0.7$7.19+7.5%$47.33 million$2.20 million0.00Upcoming Earnings
News Coverage
Gap Up
Microbot Medical logo
MBOT
Microbot Medical
1.3$6.71+2.8%$46.34 millionN/A0.00Upcoming Earnings
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$1.71+1.8%$44.11 million$200,000.00-0.71Earnings Announcement
News Coverage
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.